Opened three clinical trials in 2018 Trials in which complement dysregulation is the primary disease driver CAPSTONE, the Phase III trial in naïve …
Akari Therapeutics to Present Poster at the 23rd Congress of the European Hematology Association
NEW YORK and LONDON, June 15, 2018 - Akari Therapeutics, Plc (NASDAQ:AKTX), a biopharmaceutical company focused on the development and commercialization of …
Akari Therapeutics Receives Notice Related to Delay in 20-F Filing
NEW YORK and LONDON, May 21, 2018 - Akari Therapeutics, Plc (NASDAQ: AKTX), a biopharmaceutical company focused on the development and commercialization of …
[Read more...] about Akari Therapeutics Receives Notice Related to Delay in 20-F Filing
Akari Therapeutics Announces Fourth Quarter and Full Year 2017 Financial Results and Highlights Recent Clinical Progress
Received Regulatory Clearance in Europe to Open First Clinical Trial Site for Phase III PNH Naïve Trial CAPSTONE, the Phase III Naïve PNH Trial Expected to …
Akari Therapeutics to Present at the Leerink Partners Global Healthcare Conference
NEW YORK and LONDON, February 7, 2018 - Akari Therapeutics, Plc (NASDAQ:AKTX) (“Akari” or “the Company”), a biopharmaceutical company focused on the development …
